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Abstract: This review explores current evidence to demonstrate that botulinum neurotoxins (BoNTs)
exert antipruritic effects. Both experimental and clinical conditions in which botulinum neurotoxins
have been applied for pruritus relief will be presented and significant findings will be highlighted.
Potential mechanisms underlying antipruritic effects will also be discussed and ongoing challenges
and unmet needs will be addressed.
Keywords: botulinum neurotoxins; itch; pruritus; antipruritic; clinical; experimental
Key Contribution: This review highlights the potential utility of BoNTs to relieve pruritus. Presented
information; discussion of limitations and promising results are valuable for both researchers and
clinicians in the field.
1. Introduction
Botulinum neurotoxins (BoNTs) are protein neurotoxins that are produced by anaerobic,
spore-forming bacteria of the Clostridium genus, including Clostridium botulinum, Clostridium butyrricum,
Clostridium barati, and Clostridium argentinensis [1]. An updated review of biology, pharmacology,
and toxicology of BoNTs can be found in M. Pirazzini et al.’s excellent recent review [2]. Since its
first therapeutic use in humans in the 1980s [3], clinical use of BoNTs has significantly increased [4].
BoNTs have been used for therapeutic purposes in a diverse range of medical conditions, such as
ophthalmology, neurology, gastroenterology, urology, and psychiatry [2,4–6]. Advanced understanding
of the mechanism of action of BoNTs has led to increasing use of these molecules with novel, unique,
and desirable pharmacological properties [2]. BoNTs have also been tested in many dermatological
conditions, several of which with off-label uses [7,8]. This review focuses on the antipruritic effects
of BoNTs as presented in clinical and experimental conditions which specifically addressed potential
itch-relieving mechanisms. The aim is to highlight the value of BoNTs in an expanded evaluation as
potential antipruritic agents in future practice. It is worth mentioning that one case [9] in the literature
presented that an application of OnabotulinumtoxinA (100 U) provoked itchiness in a patient when it
was used for neuromuscular pain. In that instance, pruritus was treated with oral hydroxyzine and
camphor-menthol topical lotion [9].
2. Pruritus
Itchiness (pruritus) is a common unpleasant sensation that elicits a desire to scratch [10].
Acute itch [11] serves as a warning and self-protective mechanism to prevent potentially harmful
irritations. However, chronic itch is a challenging and significant clinical problem [12] which is often
associated with skin diseases, systemic diseases, metabolic disorders, and psychiatric disorders [13].
Although scratching temporarily relieves acute itch, persistent itch-scratch cycles often exacerbate skin
problems, disrupt sleep, and reduce the quality of life in chronic itch patients [14]. Recent studies have
documented a high prevalence of chronic pruritus (13–17%) with a lifetime prevalence of 22–26% [15].
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On the basis of international consensus, a threshold of six weeks has been set for the definition of
chronic pruritus. Chronic pruritus is a major challenge to overcome [16] and requires interdisciplinary
cooperation despite many interfering factors. Successful treatment usually involves dermatologists,
internists, general practitioners, neurologists, gynecologists, and psychiatrists [16]. An understanding
of the molecular mechanisms underlying itch has advanced the identification of itch-specific pathways
and transmitters for selective targeting [17].
Itch can broadly be categorized as either histaminergic and non-histaminergic [18]. Histamine
is released by mast and epithelial cells and binds to H1–H4 receptors, leading to the activation of
downstream target molecules within sensory neurons [17,19,20]. Histamine has been identified as the
main mediator of itch in several pruritic conditions, such as urticaria and allergic diseases. Antipruritic
treatment strategies [12] have been successfully used to target histaminergic pathways [21].
Non-histaminergic itch has attracted more attention in recent years because many chronic itch
conditions are resistant to antihistamines, necessitating the need to consider alternative treatments.
Cowhage (Mucuna pruriens) is a tropical legume known to cause itch, pricking, stinging, and burning
sensations that otherwise do not respond to antihistamines. This characteristic has made cowhage a
useful tool for studying non-histaminergic mechanisms underlying itch. When cowhage spicules
are inserted, the cysteine protease mucunain is released. When the mucanin reaches the nerve
endings of primary sensory neurons in the epidermis, it activates protease-activated receptors
(PAR) 2 and 4, which are members of the G protein-coupled receptor family [22]. Interestingly,
PAR2 and tryptase (an endogenous PAR2 agonist, the most abundant secretory granule-derived
serine proteinase released by mast cells causing itch), have been found highly elevated in patients
with atopic dermatitis (AD) [23]. Mas-related G protein-coupled receptors (Mrgprs) are involved in
the response to non-histaminergic pruritogens [24]. MrgprA3 is expressed in a sub-population of
sensory neurons known as peptidergic C-fibers and encodes pruritic effects of chloroquine, which is
an antimalarial drug [25,26]. These receptors [27,28] are also responsive to histamine, bovine adrenal
medulla 8–22 (BAM8–22), cowhage spicules, and capsaicin. Interestingly, mice lacking MrgprA3
neurons are resistant to pruritogens such as histamine, BAM8–22, SLIGRL, α-methyl-5HT, ET-1,
and chloroquine [26]. However, MrgprA3-ablated mice scratch in response to β-alanine [29]. Therefore,
MrgrpA3 positive sensory neurons are different from those neurons responding to β-alanine for
itch. MrgprD is the receptor activated by β-alanine [30], and mice lacking MrgprD do not scratch
following an intradermal injection of β-alanine [29]. Transient receptor potential (TRP) channels are
also involved in itch. Histaminergic itch transmission through TRPV1 has been reported [31]. TRPA1
is a downstream target of MrgprA3 and MrgprC11. Ablation of TRPA1 blocks itch in a dry skin mouse
model of chronic itch. Mice lacking TRPA1 exhibit no scratch following subcutaneous injections of
chloroquine and BAM8–22, but do scratch in response to α-methyl-5HT [17,32]. Voltage-gated sodium
channel (NaV) 1.7 has also been found to mediate itch. A monoclonal antibody targeting NaV 1.7
could abolish both acute and chronic itch in mice [33].
Immune cells of skin interact with nerve endings and play an important role in pathological
itch. Cytokines released from T helper 2 cells are found elevated in several pruritus conditions [34].
Interleukin-31 (IL-31) is known to play a role in AD [35]. Intradermal injection of IL-31 in mice provokes
scratching [36] that is also correlated with elevated expression of IL-31RA in the DRG (dorsal root
ganglion) [37].
Taken together, novel findings on peripheral receptors and mediators [38] present that itch
is mediated by several different subpopulations of primary sensory neurons. Some itch-provoking
substances activate overlapping populations of neurons, while others only activate distinct populations
(e.g., chloroquine vs. β-alanine; MrgprA3 vs. MrgprD). Depending on pruritogen, method of delivery,
and species, itch-related responses are variable [17]. One must also consider that a cross-talk exists
between the neurons and immune cells in the skin [38].
In addition to advancements in peripheral mechanisms of itch, several hypotheses have been
proposed for central mechanisms of itch [17,38]. Gastrin-releasing peptide (GRP) and GRP receptors
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were the first central components of itch identified in the spinal cord [39]. Ablation of inhibitory
interneurons (B5-I) in mice resulted in the development of skin lesions and scratching in mice [40].
B5-I interneurons are activated following certain transient receptor potential (TRP) channels signaling
and release dynorphin that can block itch signaling [41]. Spinal interneurons that express neuropeptide
Y also exist which mediate mechanical itch [42]. Cross-talk between neurons and central glia has also
been suggested in modulating itch [43]. For example, in a mouse model of contact dermatitis and AD,
spinal reactive astrogliosis has been reported [44]. Toll-like receptor 4 has been found to contribute to
this type of astrogliosis in a dry skin mouse model of itch [45]. Apart from astrocytes activation, spinal
microglial activation has also been found in mouse models; for example, after intradermal injection
of compound 48/80 (histamine-dependent) and 5′-guanidinonaltrindole [46]. Microglial activation
can be subsided by intrathecal minocycline (a microglial modulator) which can reduce scratching and
symptoms of dermatitis in a mouse model of AD [47].
In short, identification of peripheral and central components of itch [17,38] has pushed the field
forward for novel and effective targeting. Several established models of itch exist which are applicable
in both animals and humans. These models are useful in understanding itch pathways and also in
testing novel antipruritics [48]. Many compounds are in early stages of development and several are
going through final phases of antipruritic pipelines.
BoNTs were initially used for muscle hyperactivity [49]. Soon after the identification of broader
biological effects (e.g., neuronal and non-neuronal effects in dermal fibroblasts, sebocytes and vascular
endothelial cells), additional indications garnered attention and further mechanisms underlying BoNTs
effects were proposed [50,51]. The antipruritic effect of Botulinum Toxin Type A (BoNTA) was identified
in an open-label pilot study of lichen simplex in 2002 [52]. Its antipruritic effect in dyshidrotic hand
dermatitis was also reported in the same year [53,54]. Since then [6], BoNTs have been subjected to
investigation for many other pruritic conditions, such as Hailey-Hailey disease and inversed psoriasis.
First, one must understand how BoNTs can exert potential effects against itch. An acceptable rationale
for application of BoNTs in itch is that acetylcholine mediates itch and BoNTA inhibits the release of
acetylcholine from presynaptic vesicles. However, other mechanisms also play a role in antipruritic
effects of BoNTs. In the section below, proposed underlying mechanisms of BoNTs in reducing itch are
described. Since botulinum toxin type A (BoNTA) is the most used in the current literature, the rest of
this manuscript focuses on this neurotoxin unless otherwise stated.
3. Botulinum Toxin Type A (BoNTA)
BoNTA inhibits vesicular release of neurotransmitters by interfering with exocytotic release.
BoNTA is composed of a heavy chain with a receptor-binding site and a translocation domain as well
as a light chain with endopeptidase activity. This permits cleavage of synaptosomal-associated protein
25 (SNAP-25) which is an essential molecule for membrane fusion [55]. BoNTA was first known to
block acetylcholine release at the neuromuscular junction [56]. It has been used for disorders with
abnormal muscle contraction because of its ability to relax spastic muscles [49]. However, it became
evident that BoNTA also inhibits the release of other transmitters, such as glutamate, substance P (SP),
and calcitonin gene-related peptide (CGRP) [57]. The anti-itch effect of BoNTA is also a result of
inhibition of acetylcholine release and other mediators involved in itch [8,9]. As such, evidence from
analgesic properties of BoNTs in pain and nociception have also been inspirational for scientists [58–64].
4. Experimental Evidence for Antipruritic Effects of BoNTA in Healthy Humans
Our group was first to investigate the effect of subcutaneous administration of BoNTA on
experimentally induced itch (histamine) in healthy subjects. Fourteen healthy men received BoNTA
(5U, BOTOX®, Allergan, NJ, USA) on the volar forearm. Saline was used as control. Histamine
prick tests were performed at the application sites before, one, three days, and a week after
treatments. Itch intensity and neurogenic inflammation were evaluated. BoNTA significantly reduced
histamine-evoked itch intensity, flare size, and vasomotor reactions to histamine [65].
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Another study in healthy volunteers looked into the antipruritic effects of BoNTA in a
non-histaminergic model where cowhage was used (clinicaltrials.gov; identifier: NCT02639052). In this
study, 35 healthy subjects (16 men and 19 women; age 26.8 ± 6.8 years) were enrolled and intradermal
BoNTA (10U, BOTOX®, Allergan, NJ, USA) was injected in a 4 × 4 cm area on volar arms. Saline was
used as control. Itch intensity following application of cowhage was recorded before treatment and
one week, one month, and three months post-treatment. BoNTA reduced cowhage-evoked itch at all
time points, suggesting a long-lasting effect. This study was presented at the 9th World Congress on
Itch [66].
5. Experimental Evidence for Antipruritic Effects of BoNTA in Animal Models
Animal studies have also been conducted to look deeper into the cellular-molecular mechanism(s)
of antipruritic effects of BoNTA.
It is generally accepted that TRPV1 (transient receptor potential cation channel subfamily V
member 1) is essential for histamine-dependent itch [31], whereas TRPA1 (transient receptor potential
ankyrin 1) is required for histamine-independent itch, e.g., chloroquine-evoked itch, bile acids-induced
cholestatic itch [67], and oxidative stress-induced itch [68,69]. A mice study [70] has investigated
the effects of BoNTA on acute and chronic itch and the possible association of TRP channels to
antipruritic mechanisms of BoNTA. Findings from this study demonstrated that BoNTA inhibited
chloroquine-evoked itch which is considered an acute non-histaminergic model similar to that of
compound 48/80-induced itch. Compound 48/80 is a potent histamine-releasing agent, primarily from
mast cells, with a subsequent depletion of tissue histamine [71]. It was also presented that, following
a single intradermal injection of BoNTA (0.1 U) into the nape of the neck, mRNA expression of TRPV1
and TRPA1 notably decreased in DRG and lasted for seven days. Protein expression of TRPA1 was
highly elevated following AEW (acetone–diethylether–water) treatment—a dry skin itch model—and
pretreatment with BoNTA could significantly abolish upregulation of TRPA1 expression in this model.
Authors proposed that TRPV1 and TRPA1 play an important role in both acute and chronic itch
and that BoNTA might exert its anti-itch effects through downregulated expression of TPRV1 and
TPRA1 in DRG [70]. This study confirmed that antipruritic effects of BoNTA present independently of
mice models and can be used both for histamine-dependent and histamine-independent itch and dry
skin-induced chronic itch [70].
Another study studied AD in mice models [72]. AD is accompanied by debilitating itch and
a complex interaction is believed to exist between immune cells and nerve fibers [73]. NC/Nga mouse
is a relevant animal model to study AD [74] because these animals spontaneously develop AD-like skin
lesions under conventional conditions. In this study [72], the authors examined the protective effect
of BoNTA (intradermal injection on the rostral back) on AD lesions in NC/Nga mouse. The primary
outcome was skin thickness and transepidermal water loss. Authors assessed skin thickness, water
loss, skin severity scores, histological alterations of skin, e.g., mast cell count, skin interleukin (IL)-4
mRNA and protein expression, and total serum IgE levels [72].This study showed that BoNTA could
significantly suppress AD severity, IL-4 expression level, and the number of infiltrating mast cells [72].
Study period was limited to 14 days and long-term effects were not investigated.
The effects of BoNTA on mast cell activity has also been studied in animal models [75,76].
In a study by Park [75], 10 Sprague Dawley rats were randomly divided into two groups receiving
BoNT A and vehicle (control). A distally based 3 × 9 cm random pattern flap including the panniculus
carnosus muscle was elevated. BoNTA was administered five days prior to flap elevation. Seven days
after flap elevation, tissue samples (1 × 1 cm) were taken from the center of each flap. Findings [75]
demonstrated that BoNTA decreased mast cell activity.
Another animal study looked into the mechanisms of BoNTA in targeting psoriasis. In a KC-Tie2
mouse model of psoriasis [77], researchers showed that intradermal injection of BoNTA improved
psoriasiform skin inflammation and epidermal hyperplasia. It also decreased the number of infiltrating
CD4+ T cells and CD11c+ dendritic cells (DCs) in parallel with reducing the number of blood vessels
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and their adjacent nerves [77]. The decreased number of blood vessels within the affected skin of the
treated mice illustrates the role of nerves and blood vessels in an inflammatory skin disease such as
psoriasis. This study illustrates the role of blood vessel and nerve communication in psoriasis and
the potential role of BoNTA in blocking this communication. Authors proposed that the persistence
of some plaques in psoriasis patients might be explained by local microenvironments within the
tissue, including nerve-derived SP and CGRP [77]. BoNTA, a known inhibitor of CGRP and SP release,
can help with the interruption of this cascade and may present significant improvement in disease
severity as early as two weeks after treatment. Therefore, they proposed that BoNTA may serve as a
supplemental agent to topical or biologic therapeutic regimens [77].
6. Clinical Evidence for Antipruritic Effects of BoNTs
BoNTs have been used in clinics for many dermatological conditions that can present with or
without itch. For a review, see A. Campanati et al., Y.S. Kim et al., and A.S. Al-Ghamdi et al. [7,8,78].
A recent review has summarized the use of intradermal BoNTA in treating chronic refractory pruritus
based on 11 studies between 1996 and 2016 [79].
Many applications are still off-label [7] and the cases presented below both summarize
current clinical evidence and encourage additional well-designed studies to reach a consensus
on safe applicability, optimal dose, and delivery route for the standardization of BoNTs use for
antipruritic effects.
6.1. Post Herpetic Itch
Post herpetic itch (PHI) is considered a type of neuropathic itch and has been investigated less
than postherpetic neuralgia (PHN) [80]. PHN is a long-term neuropathic pain that remains after
the rash from shingles (also known as herpes zoster) has healed. Varicella-zoster virus (VZV) is the
cause of herpes zoster. Besides shingles, degenerative nerve root compression (notalgia paresthetica),
and sensory polyneuropathy can cause neuropathic itch [81]. Almost half of PHN patients report PHI.
This finding suggests that mechanisms underlying PHI and PHN are most likely independent [82].
PHI is a common disorder that equally affects men and women. PHI is age-independent and occurs in
both young and old patients. PHI often appears on the head and neck (V1 dermatome) [82].
BoNTA treatment has been successful to reverse pain in PHN [83]. Accordingly, the usefulness of
BoNTA in PHI has been considered [84] and the effectiveness of BoNTA for a neuropathic itch caused
by dermatomal damage to the thoracic nerves has been presented [84]. In this study, BoNTA injections
(dose range 16–25 U) were given in several points within the involved dermatome. Double-blind,
randomized, control trials are required in a larger sample size before the use of BoNTA in different
types of neuropathic itch such as PHI can be considered. BoNTs could be considered in severe cases of
intractable PHI, which are not responsive to other options [80].
6.2. Brachioradial Pruritus
Brachioradial pruritus (BRP) was first described in Florida in 1968 by Waisman [85] and is
classified as a deep itch of the forearms and upper trunk which can worsen with either scratching or
sunlight [86]. Brachioradial pruritus is considered another neurogenic itch which often occurs in the
upper extremities, usually localized on the dorsolateral forearm overlying the proximal head of the
brachioradialis muscle; however, upper arms and shoulders may also be affected [87,88]. BRP might
be unilateral or bilateral and it is still considered a common “tropical” dermopathy [89]. It is still not
known if BRP is a symptom of neuropathy, similar to chronic cervical radiculopathy, or a condition
that occurs secondary to chronic ultraviolet damage. Larger studies for better understanding of
BRP are warranted. BRP responds to ice packs but efficacy is only temporary [90]. Lamotrigine
and gabapentin have also been found useful for BRP. Intradermal injections of BoNTA (100 IU) was
reported in a 59-year-old Caucasian female with BRP for 12 years [86]. This patient had disabling itch
and a burning sensation on the upper posterior arms, scapular regions, and neck. A diverse range
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of topical and systemic treatments, hypnotherapy, and Chinese herbal medicine did not improve the
patient’s condition. Application of icepacks was not beneficial in this case. However, this patient
reported dramatic itch relief, lasting for up to six months, after four rounds of BoNTA injections. It was
proposed that the effect of BoNTs for this condition and those similar to it, may have been due in part
to its ability to block the release of neurotransmitters involved in itch, e.g., acetylcholine.
6.3. Notalgia Paresthetica
Notalgia paresthetica (NP) [91,92] is a sensory neuropathic syndrome with pruritus, pain, paresthesia,
hypo-hyper-esthesia, and burning as common symptoms. NP is characterized by a brownish itchy patch
in the affected area. This condition mainly occurs in the elderly or in association with musculoskeletal
disorders driven by spinal nerve compression, particularly at the C4–C6 level [92]. NP is a difficult
condition to treat and quality of life is rather low in these patients. Less efficient treatments for NP are
partially attributable to its unidentified underlying mechanisms or pathogenesis.
In 2007, two NP patients were treated with BoNTA [84]. Later in 2010, Wallengren and Bartosik [93]
reported limited effectiveness of BoNTA treatment in six NP patients. One double-blind randomized
clinical trial for NP was reported in 2014 [94], in which the effectiveness of BoNTA was tested in
20 NP patients who were resistant to topical therapies. The study investigated pruritus, effects on
hyperpigmentation, and global effectiveness as rated by both patients and investigators. Pruritus
rated on VAS (visual analogue scale) did not show any itch reduction when it was compared between
patients and controls (receiving saline) [94]. BoNTA treatment also did not improve hyperpigmentation
or global efficacy indicators. In this study, injections of 0.1 mL (50 U/mL) for every 1–2 cm2 of
hyperpigmented area were given. Maximum dose reached to 200 U [94].
Injection of BoNTA is an option, but further research is required to confirm safety and efficacy of
BoNTA for NP. Patient selection and dose also need to be determined.
6.4. Lichen Simplex Chronicus (LSC)
Lichen simplex chronicus (LSC) is also known as neurodermatitis circumscripta. LSC is an
eczematous dermatosis, characterized by intense localized pruritus and thickening of the skin
with variable scaling arising secondarily from repetitive scratching or rubbing. This condition can
be intense or recurrent and often disrupts sleep, sexual function, and quality of life in affected
individuals. Breaking the itch-scratch cycle is challenging. Exact incidence in general population
is unknown, but one study demonstrated that 12% of aging patients with pruritic skin presented
with LSC [95]. This disorder is observed more commonly in females than in males. BoNTA has been
considered an option for LSC [52]. One pilot study investigated the effect of intradermal injection of
Abobotulinumtoxin A in five lesions in three patients and found that pruritus diminished within three
to seven days in all patients. By four weeks, all lesions had cleared completely with no recurrences [96].
Another case study reported a successful result with BoNTA in a 55-year-old woman with a six-year
history of intense facial pruritus at the right side of face [97]. Despite the small sizes of these studies, the
antipruritic effects of BoNTA in LSC is promising [78]; however, additional large studies are required
to confirm its efficacy in LSC.
6.5. Vulvodynia
Vulvodynia is a complex disorder [98] affecting 16% of women in the general population.
It is described by burning, stinging, itching, irritation, or rawness. The International Society for
the Study of Vulvovaginal Disease (ISSVD) has defined vulvodynia as “vulvar pain occurring in
the absence of an underlying recognizable disease.” There are no clinical or histopathologic criteria
for the diagnosis other than consideration and careful evaluation to exclude other causes of pain.
Successful therapy often requires a multidisciplinary approach with more than one type of therapeutic
intervention. BoNTA has been shown to be effective treatment for vulvodynia [99]. While several small
open-label studies have shown improvement in symptoms with botulinum toxin at doses of 20–100
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units, the only randomized double-blind, placebo-controlled trial demonstrated no improvement with
20 units over placebo in 64 women with vulvodynia [100].
6.6. Keloids and Hypertrophic Scars
Keloids and hypertrophic scars are structures formed during the wound healing process and
present with dysregulated growth and a high level of collagen formation. To prevent these scars,
silicone dressings, laser therapy, and immune response modulators are applied [101]. Intralesional (IL)
corticosteroid therapy with triamcinolone acetonide is a common therapy in keloids treatment [102].
In 2000, Gassner and colleagues [103] suggested that BoNTA injections can paralyze muscles close
to wounds and subsequently reduce pressure on wound edges. This first study was conducted in
a primate model and confirmed the hypothesis. Another study used optical 3D profilometry as an
objective evaluation of keloids following treatment by BoNTA [104]. Only four patients were included
in this study and no changes was evident on fibroblast proliferation. In a rabbit ear hypertrophic
scar model [105], BoNTA also was found to have less effect on hypertrophic index, fibroblast density,
and collagen density when it was compared with IL triamcinolone acetonide and 5-fluorouracil [106].
However, other in vitro and experimental animal models support BoNTA as treatment of keloids
and scars [107]. BoNTA delays fibroblast growth through the inhibition of the cell cycle which
subsequently reduces hypertrophic scar development. BoNTA also decreases the expression of
connective tissue growth factor and inhibits the growth of fibroblasts and scar expansion. BoNTA
reduces the concentration of TGF-β1 in fibroblasts and decreases the infiltration of inflammatory cells
during wound healing; it also reduces fibrosis [107].
In 2015, a large randomized double-blind study tested the effect of BoNTA compared with IL
corticosteroid therapy in 24 patients with keloids [108]. In this study, patients were allocated to receive
IL steroid every four weeks for six sessions and IL BoNTA 5 IU/cm every eight weeks for three
sessions. Hardness, elevation, and redness, together with itching, pain, and tenderness were evaluated
and patients were asked for their subjective satisfaction. No significant difference was observed
between groups in most of the measured parameters. However, patients receiving BoNTA reported
higher satisfaction with their therapy. Authors proposed that BoNTA might have reduced small-fiber
neuropathy causing itching, pain, and allodynia [108].
A potential use for BoNTA in keloids and hypertrophic scars is predicted. But additional
randomized double-blind controlled trials are needed to compare with current treatments to evaluate
efficacy and safety profile. Efficacy in the prevention and treatment of hypertrophic scars might vary
according to the scar’s location on the body; hence, testing both facial and other body parts such
as chest or back is proposed. Surgical and trauma wounds must also be differentiated. In addition,
stratification according to ethnicity and age is essential as both elements affect wound healing.
6.7. Psoriasis
Psoriasis is a skin disorder strongly linked to both genetic and environmental factors.
An immunological reaction mediated by T lymphocytes is thought to be the main player in the
pathogenesis of psoriasis. Cutaneous inflammation and keratinocyte hyperproliferation are featured
characteristics of such a response.
Inverse or flexural psoriasis is a specific form of psoriasis with red, dry, smooth, and shiny
skin. Clinically, inverse psoriasis manifests with sharply demarcated erythematous plaques with
infiltration that accompany sensations of itching and burning. Common locations of inverse psoriasis
include armpits, groin, under the breasts, and in other flexion skin folds, such as around the genitals
and buttocks. It is particularly troublesome for patients with deep skin folds and/or those who
are overweight. Treatment of inverse psoriasis can be difficult. Steroid creams and ointments are
considered effective; however, overuse of steroids can result in side effects, especially thinning of
the skin and stretch marks. Skin folds, where inverse psoriasis is common, are susceptible to yeast
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and fungal infections. Topical immunomodulators, such as tacrolimus and pimecrolimus, have also
been effective.
Administration of BoNTA has been proposed as a novel therapy in inverse psoriasis [109,110]
in consideration of its mechanism of action in the neuroglandular junction, which reduces sweating.
However, a link between high nerve fiber density in psoriatic skin and elevated CGRP and SP release
has been reported. It has been demonstrated that psoriasis undergoes remission phases as a result
of innervation loss or lack of nerve function, such as following a nerve injury. This can explain
how BoNTA inhibits CGRP and SP release from nerve endings and can lead to subjective reports of
improvement after administration of BoNTA.
Zanchi and colleagues [109] reported that in 15 patients with inverse psoriasis, BoNTA presented
effectiveness; however, the effect was mainly evaluated by self-assessment in patients rating itch
and pain on a visual analogue scale (VAS). In this study, psoriasis that was located in the armpits,
submammary sulcus, intergluteal folds, inguinal folds, and umbilicus in patients was treated with
BoNTA injections with a total dose of 50–100 U per patient relative to psoriasis extent and severity.
Evaluations were performed before and after treatment in weeks 2, 4, and 12. The erythematous area
was defined using objective photographic evidence and subjective patient assessment of pain and itch
was assessed using a 10-point VAS. BoNTA therapy resulted in improvements in subjective patient
symptomatology and objective reductions in erythema and maceration in the treated areas according
to photographic evidence. However, findings from this study were questioned [111], pointing to the
lack of quantitative assessment for improvement; for example, using psoriasis area and severity index
(PASI) or obtaining histological evident before and after the treatment.
Overall, current evidence demonstrates that BoNTA is capable of reducing pain, itch,
and inflammation in psoriasis-affected skin. Dermal and epidermal cytokines and peptides produced
by keratinocytes, fibroblasts, lymphocytes, and macrophages are involved in the pathogenesis of
psoriasis. Interleukin-1 (IL-1) stimulates the proliferation of keratinocytes and the production of
cellular adhesion molecules which then stimulate the release of other cytokines (e.g., IL-6, IL-8).
IL-6 stimulates the proliferation of B and T lymphocytes, which is an important factor in stimulating
keratinocyte growth, and IL-8 exerts a powerful chemotaxis action towards leucocytes. In future
randomized clinical trials evaluating the potential role of BoNTA in the treatment of psoriasis, special
attention needs to be given to psoriasis as a variable pathology with several spontaneous relapses
and remissions over time which can cause difficulties in evaluation of effectiveness. Amount and
depth of injection are yet to be determined. Assessment of effectiveness must include both subjective
and objective parameters including cutaneous sensory, vasomotor, and autonomic function. Safety,
tolerability, and cost effectiveness should also be carefully evaluated before considering BoNTA as a
routine clinical practice.
6.8. Pompholyx
Dyshidrotic eczema, also called pompholyx, is a common relapsing vesicular-bullous disease
found on the palm or soles of feet [112]. The pathogenesis of this condition is still unresolved; however,
one study examined the roles of aquaporin 3 and aquaporin 10, which are water channel proteins
located in the epidermis, and concluded that overexpression of these channels may play a role [113].
Wet works, sweating, and occlusion are among the provoking factors. Pain, itch, and burning sensations
together with discomfort in wearing gloves or shoes, bacterial infection, or mycosis are among the
common symptoms.
An improvement in hand eczema was observed in patients with palmar hyperhidrosis following
intradermal BoNTA [53]. This study was conducted in 10 patients with bilateral vesicular hand
dermatitis where BoNTA injections (100 U BOTOX®) or saline (control) were given in either hand.
Seven out of the 10 patients reported a good or very good effect of the treatment. Another study [54]
applied topical corticosteroids on both hands in combination with intracutaneous injections of BoNTA
(100 U BOTOX®) in six patients with more severely affected hands. A rapid improvement in pruritus
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and vesiculation was observed in the treated hand with combination therapy. A case study [114]
has also demonstrated BoNTA effects in palmar pompholyx. No placebo-controlled trial is available.
Therefore, effective and safe application of BoNTA for dyshidrotic eczema requires further validation.
6.9. Postburn Itch
Itching is a common secondary symptom related to burn injuries [115]. Research has proposed
multiple mechanisms underlying itch as secondary to burn conditions. Several medications have
been identified and used to manage this condition. BoNTA has also been considered as an option.
In 2012, a study was conducted [116] to investigate the effectiveness of BoNTA and found that 87.5%
of patients rated their postburn itch as severe (>7). Following the administration of BoNTA, itch
intensity dropped to zero within four weeks. The average duration of the symptom-free period was
nine months (range 3–18 months). BoNTA might be an option for burn-associated itch which are
resistant to conventional therapies. This study [116] only included a small sample size and larger
studies are warranted before establishment of this treatment at clinic.
6.10. Fox–Fordyce Disease
Fox–Fordyce disease (FFD), characterized by intensely pruritic papules in apocrine gland-bearing
regions, is a rare disorder for which there is currently no definitive treatment or known cure [117].
FFD is a chronic, pruritic disorder caused by keratin plugging of the follicular infundibulum at the distal
portion of the apocrine sweat duct and less often by plugging of apoeccrine ducts. This obstruction
causes apocrine sweat retention and, over time, rupture of glands with secondary inflammatory
dermal alterations. The etiology remains unclear although epidemiological data support a hormonal
component, as women between 15 and 35 years of age are more commonly affected and this condition
may remit after menopause.
The condition is often intensely pruritic and is usually associated with hypohidrosis. Pruritus
is aggravated by emotional, physical, or pharmacological stimulations that enhance sweating.
Therapeutic knowledge of FFD is derived from case reports but no large case series has been carried
out. Topical and intralesional corticosteroids are often a first-line therapy. In medication-refractory
cases, surgical interventions have proven to be successful. A case has been presented in which BoNTA
injections resulted in the disappearance of pruritus and a partial clinical response after one session [117].
This response was sustained over time. The study’s authors suggested that chemodenervation of
cholinergic nerve terminals to the eccrine and apoeccrine glands, inhibiting their sweat secretion, might
be considered as underlying mechanism for the effects seen in this case. Other cases of hyperhidrotic
pruritic axillary granular parakeratosis responders to BoNTA have also been reported [118]. Clinical
trials to evaluate optimal treatment regimen with BoNTA for FFD are required.
6.11. Hailey-Hailey Disease
Hailey-Hailey disease (familial benign pemphigus) is a rare genetic skin disease, often presented
with blisters or vesicles and erythematous plaques in skin folds. Axilla, groin, neck, and inframammary
folds are amongst the most common sites of disease manifestation. The disease’s associated red scaly
areas can be itchy. The topical and oral corticosteroids, oral retinoid, cyclosporine, and methotrexate
used for treatment are often linked to side effects. There are cases of Hailey-Hailey disease treated
with BoNTA with successful outcome [119,120]. Reduced sweating and local irritation help to improve
lesions conditions as well as a reduction in itch. BoNTA can potentially be considered as a treatment
option, in particular for those patients with limited response or intolerance to other treatments [120].
6.12. Rhinitis
Rhinitis is an inflammation of the nasal mucous membranes, presented with nasal discharge,
nasal obstruction, sneezing, and itching [121,122]. It is a common disease affecting around 20% of
general population and can be divided into infectious, allergic, occupational, drug-induced, hormonal,
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and idiopathic rhinitis (IR). The latter is also known as non-allergic, noninfectious perennial rhinitis,
intrinsic, or vasomotor rhinitis. BoNTs have been used in both allergic [123] and idiopathic rhinitis
(IR) [124,125].
Allergic rhinitis (AR) is a noninfectious inflammatory disorder in nasal mucosa provoked
by an allergen exposure and an IgE-mediated immune response. The major mediator of nasal
inflammation in AR is histamine which causes symptoms such as vascular permeability, mucus
secretion, and stimulation of the sensory nerve fibers. Other mediators involved are neurokinin A, SP,
CGRP, VIP, and neurotrophins. Current treatments include intranasal corticosteroids, antihistamines,
mast cell stabilizers, and leukotriene receptor antagonists. AR can benefit from BoNTA injection, when
it is given intranasally [124]. No serious adverse or systemic effects have been noted but burning
after injection, nasal dryness, and epistaxis have been recorded. Nasal injection of BoNTA has shown
comparable therapeutic effect to cetirizine in AR [126]. Arguments for the use of BoNTA in rhinitis are
grounded in its modulatory effect on the secretory tone, which is related to the action of autonomic
nervous system. A similar rationale has been used for the positive effects of BoNTA in Frey syndrome,
hyperhidrosis, and sialorrhea. AR’s symptoms result from the activation of inflammatory mediators
and an imbalance in the autonomic nervous system. Histamine, prostaglandin, and leukotrienes
enhance vascular permeability and produce edema, in addition to altering the balance of the autonomic
nervous system [127]. Underlying mechanisms of IR remain to be elucidated; however, autonomic
nervous system imbalance with a dominant parasympathetic tone in the nasal mucosa has been
proposed. Nasal blockage and rhinorrhea are more common in IR, while itching and sneezing are
mostly present in AR. All symptoms can be prevented by application of BoNTA.
Several other mechanisms for BoNTA effect in nasal mucosa have been proposed [124].
For example, BoNTA can induce apoptosis in the nasal glands, inhibit acetylcholine release from nasal
mucosa nerve endings, decrease the release of neuropeptides (e.g., VIP and SP) from the trigeminal and
parasympathetic nerve endings, and inhibit acetylcholine release from preganglionic cholinergic nerve
endings in the sphenopalatine ganglion. As such, it has been suggested that targeting an upstream
source of parasympathetic innervation at the sphenopalatine ganglion can potentially affect both
nasal mucosa and nasal glands to yield an additive effect from the intraganglionic injection. A study
proposed a technique to inject BoNTA into the posterior lateral nasal wall, which is located adjacent
to the sphenopalatine ganglion. They conducted a pilot study with this technique applying a low
dose of 25 units, resulting in only moderate discomfort to participants but yielding safe and effective
results. Improved effects on congestion and itch had already been seen with dosages above 12 units.
Accordingly, the authors suggested that low dose administration of BoNTA can be advantageous from
a safety perspective.
BoNTA also may be considered in patients resistant to other treatments or intolerant to current
treatments, e.g., nasal corticosteroids or systemic antihistamines. This treatment also allows for
longer lasting effects, beneficial for patients. However, larger studies are required to identify the
long-term effects and safety profile of BoNTA [126]. Further investigation is needed to identify
whether BoNTA is to be used in clinic for rhinitis and which technique would yield the optimal
outcome (e.g., posterior injection, turbinate injection, septal injection, or topical) [128]. RT001 is a novel
topical gel formulation which contains a purified 150kDa BoNTA protein that has been used in a rat
model [129]. The gel formula includes a prietary peptide to enhance transcutaneous and transmucosal
flux of BoNTA. In the model, after a single intranasal administration of RT001, associated clinical signs
of rhinitis, including inflammation, were significantly resolved within 5 days after treatment.
The optimal dose and patient selection also need to be determined. In addition, it is still unclear
whether and how repetitive administration of BoNTA would influence the outcome. Desensitization
following repeated application is still an open question. Another important point is that some outcome
measures are difficult to be objectified, for instance, nasal pruritus. Hence, analyzing effectiveness calls
for the development of some objective methods to complement existing subjective instruments.
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7. Concluding Remarks and Future Perspectives
This review highlighted the potential for BoNTs with a major focus on BoNTA to relieve pruritus.
A lack of a sufficient number of randomized controlled trials, limited sample size in the current
literature, diverse range of outcome measures, and a lack of knowledge about placebo effects make it
difficult to draw a firm conclusion on the antipruritic effects of BoNTs. In addition, for each condition,
several critical components remain unidentified, including safe and effective dosage, route of delivery
(also considering new formulations of BoNTs), single versus repeated application with optimal interval,
and standardization of techniques used in outcome measures. In addition, a strategy for patient
selection and precise identification of responders in terms of gender, age, and ethnic background
would substantially aid in targeting the right group for optimal effect. The long-lasting effects of BoNTs
make it desirable in terms of patients’ compliance. However, measured use must also be considered in
terms of cost and comparable effectiveness with other agents available for each pruritus condition.
Most of the studies presented in the literature have suggested BoNTA as an option; however, not as a
first-line therapy and predominantly for those patients either who are having recurrent problems or
who are non-responders to other treatment options. It is likely only a matter of time before the full
potential of BoNTs for pruritus is elucidated. However, for the time being, focus should be on more
common conditions or those for which stronger evidence exists for successful use of BoNTs can be on
those conditions that are more common and stronger evidence exist in the literature for successful use
of BoNTs.
Conflicts of Interest: The author has no relevant affiliations or financial involvement with any organization
or entity with a financial interest in or financial conflict with the subject matter or materials discussed in this
manuscript. No writing assistance was utilized in the production of this manuscript.
References
1. Brin, M.F. Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl. 1997, 6,
S146–S168. [CrossRef]
2. Pirazzini, M.; Rossetto, O.; Eleopra, R.; Montecucco, C. Botulinum neurotoxins: Biology, pharmacology,
and toxicology. Pharmacol. Rev. 2017, 69, 200–235. [CrossRef] [PubMed]
3. Scott, A.B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery.
Ophthalmology 1980, 87, 1044–1049. [CrossRef]
4. Dressler, D. Clinical applications of botulinum toxin. Curr. Opin. Microbiol. 2012, 15, 325–336. [CrossRef]
[PubMed]
5. Luvisetto, S.; Gazerani, P.; Cianchetti, C.; Pavone, F. Botulinum toxin type a as a therapeutic agent against
headache and related disorders. Toxins 2015, 7, 3818–3844. [CrossRef] [PubMed]
6. Wollina, U. Botulinum toxin: Non-cosmetic indications and possible mechanisms of action. J. Cutan. Aesthet. Surg.
2008, 1, 3–6. [CrossRef] [PubMed]
7. Campanati, A.; Martina, E.; Giuliodori, K.; Consales, V.; Bobyr, I.; Offidani, A. Botulinum toxin off-label use
in dermatology: A review. Skin Appendage Disord. 2017, 3, 39–56. [CrossRef] [PubMed]
8. Kim, Y.S.; Hong, E.S.; Kim, H.S. Botulinum toxin in the field of dermatology: Novel indications. Toxins 2017, 9, 403.
[CrossRef]
9. Ho, D.; Jagdeo, J. Pruritus associated with onabotulinumtoxina treatment of neuromuscular pain. J. Drugs Dermatol.
2015, 14, 199–200. [PubMed]
10. Ikoma, A.; Steinhoff, M.; Stander, S.; Yosipovitch, G.; Schmelz, M. The neurobiology of itch. Nat. Rev. Neurosci.
2006, 7, 535–547. [CrossRef] [PubMed]
11. Green, D.; Dong, X. The cell biology of acute itch. J. Cell Biol. 2016, 213, 155–161. [CrossRef] [PubMed]
12. Grundmann, S.; Stander, S. Chronic pruritus: Clinics and treatment. Ann. Dermatol. 2011, 23, 1–11. [CrossRef]
[PubMed]
13. Stander, S.; Weisshaar, E.; Mettang, T.; Szepietowski, J.C.; Carstens, E.; Ikoma, A.; Bergasa, N.V.; Gieler, U.;
Misery, L.; Wallengren, J.; et al. Clinical classification of itch: A position paper of the international forum for
the study of itch. Acta Derm. Venereol. 2007, 87, 291–294. [CrossRef] [PubMed]
Toxins 2018, 10, 143 12 of 17
14. Kini, S.P.; DeLong, L.K.; Veledar, E.; McKenzie-Brown, A.M.; Schaufele, M.; Chen, S.C. The impact of pruritus
on quality of life the skin equivalent of pain. Arch. Dermatol. 2011, 147, 1153–1156. [CrossRef] [PubMed]
15. Carr, C.W.; Veledar, E.; Chen, S.C. Factors mediating the impact of chronic pruritus on quality of life.
JAMA Dermatol. 2014, 150, 613–620. [CrossRef] [PubMed]
16. Stander, S.; Zeidler, C.; Magnolo, N.; Raap, U.; Mettang, T.; Kremer, A.E.; Weisshaar, E.; Augustin, M. Clinical
management of pruritus. J. Dtsch. Dermatol. Ges. 2015, 13, 101–115. [CrossRef] [PubMed]
17. Lee, J.S.; Han, J.S.; Lee, K.; Bang, J.; Lee, H. The peripheral and central mechanisms underlying itch. BMB Rep.
2016, 49, 474–487. [CrossRef] [PubMed]
18. LaMotte, R.H.; Dong, X.Z.; Ringkamp, M. Sensory neurons and circuits mediating itch. Nat. Rev. Neurosci.
2014, 15, 19–31. [CrossRef] [PubMed]
19. Bell, J.K.; McQueen, D.S.; Rees, J.L. Involvement of histamine h4 and h1 receptors in scratching induced by
histamine receptor agonists in balb c mice. Br. J. Pharmacol. 2004, 142, 374–380. [CrossRef] [PubMed]
20. Strasser, A.; Wittmann, H.J.; Buschauer, A.; Schneider, E.H.; Seifert, R. Species-dependent activities of
g-protein-coupled receptor ligands: Lessons from histamine receptor orthologs. Trends Pharmacol. Sci.
2013, 34, 13–32. [CrossRef] [PubMed]
21. Akiyama, T.; Carstens, E. Neural processing of itch. Neuroscience 2013, 250, 697–714. [CrossRef] [PubMed]
22. Nystedt, S.; Emilsson, I.E.; Wahlestedt, C.; Sundelin, J. Molecular-cloning of a potential proteinase activated
receptor. Proc. Natl. Acad. Sci. USA 1994, 91, 9208–9212. [CrossRef] [PubMed]
23. Steinhoff, M.; Neisius, U.; Ikoma, A.; Fartasch, M.; Heyer, G.; Skov, P.S.; Luger, T.A.; Schmelz, M.
Proteinase-activated receptor-2 mediates itch: A novel pathway for pruritus in human skin. Exp. Dermatol.
2004, 13, 529–591. [CrossRef]
24. Liu, Q.; Dong, X. The role of the mrgpr receptor family in itch. Handb. Exp. Pharmacol. 2015, 226, 71–88.
[PubMed]
25. Han, L.; Ma, C.; Liu, Q.; Weng, H.J.; Cui, Y.; Tang, Z.; Kim, Y.; Nie, H.; Qu, L.; Patel, K.N.; et al.
A subpopulation of nociceptors specifically linked to itch. Nat. Neurosci. 2013, 16, 174–182. [CrossRef]
[PubMed]
26. Liu, Q.; Tang, Z.; Surdenikova, L.; Kim, S.; Patel, K.N.; Kim, A.; Ru, F.; Guan, Y.; Weng, H.J.; Geng, Y.; et al.
Sensory neuron-specific gpcr mrgprs are itch receptors mediating chloroquine-induced pruritus. Cell 2009, 139,
1353–1365. [CrossRef] [PubMed]
27. Lembo, P.M.; Grazzini, E.; Groblewski, T.; O’Donnell, D.; Roy, M.O.; Zhang, J.; Hoffert, C.; Cao, J.; Schmidt, R.;
Pelletier, M.; et al. Proenkephalin a gene products activate a new family of sensory neuron-specific gpcrs.
Nat. Neurosci. 2002, 5, 201–209. [CrossRef] [PubMed]
28. Sikand, P.; Dong, X.; LaMotte, R.H. Bam8-22 peptide produces itch and nociceptive sensations in humans
independent of histamine release. J. Neurosci. 2011, 31, 7563–7567. [CrossRef] [PubMed]
29. Liu, Q.; Sikand, P.; Ma, C.; Tang, Z.; Han, L.; Li, Z.; Sun, S.; LaMotte, R.H.; Dong, X. Mechanisms of itch
evoked by beta-alanine. J. Neurosci. 2012, 32, 14532–14537. [CrossRef] [PubMed]
30. Shinohara, T.; Harada, M.; Ogi, K.; Maruyama, M.; Fujii, R.; Tanaka, H.; Fukusumi, S.; Komatsu, H.;
Hosoya, M.; Noguchi, Y.; et al. Identification of a g protein-coupled receptor specifically responsive to
beta-alanine. J. Biol. Chem. 2004, 279, 23559–23564. [CrossRef] [PubMed]
31. Shim, W.S.; Tak, M.H.; Lee, M.H.; Kim, M.; Kim, M.; Koo, J.Y.; Lee, C.H.; Kim, M.; Oh, U. Trpv1 mediates
histamine-induced itching via the activation of phospholipase a2 and 12-lipoxygenase. J. Neurosci. 2007, 27,
2331–2337. [CrossRef] [PubMed]
32. Gamper, N. Itchy channels and where to find them. J. Physiol.-Lond. 2017, 595, 3257–3259. [CrossRef]
[PubMed]
33. Lee, J.H.; Park, C.K.; Chen, G.; Han, Q.J.; Xie, R.G.; Liu, T.; Ji, R.R.; Lee, S.Y. A monoclonal antibody that
targets a na(v)1.7 channel voltage sensor for pain and itch relief. Cell 2014, 157, 1393–1404. [CrossRef]
[PubMed]
34. Storan, E.R.; O’Gorman, S.M.; McDonald, I.D.; Steinhoff, M. Role of cytokines and chemokines in itch.
Handb. Exp. Pharmacol. 2015, 226, 163–176. [PubMed]
35. Nattkemper, L.A.; Martinez-Escala, M.E.; Gelman, A.B.; Singer, E.M.; Rook, A.H.; Guitart, J.; Yosipovitch, G.
Cutaneous t-cell lymphoma and pruritus: The expression of il-31 and its receptors in the skin. Acta Derm. Venereol.
2016, 96, 894–898. [CrossRef] [PubMed]
Toxins 2018, 10, 143 13 of 17
36. Arai, I.; Tsuji, M.; Takeda, H.; Akiyama, N.; Saito, S. A single dose of interleukin-31 (il-31) causes continuous
itch-associated scratching behaviour in mice. Exp. Dermatol. 2013, 22, 669–671. [CrossRef] [PubMed]
37. Arai, I.; Tsuji, M.; Miyagawa, K.; Takeda, H.; Akiyama, N.; Saito, S. Repeated administration of il-31
upregulates il-31 receptor a (il-31ra) in dorsal root ganglia and causes severe itch-associated scratching
behaviour in mice. Exp. Dermatol. 2015, 24, 75–78. [CrossRef] [PubMed]
38. Sanders, K.M.; Nattkemper, L.A.; Yosipovitch, G. Advances in understanding itching and scratching: A new
era of targeted treatments. F1000Res 2016, 5. [CrossRef] [PubMed]
39. Sun, Y.G.; Chen, Z.F. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord.
Nature 2007, 448, 700–703. [CrossRef]
40. Ross, S.E.; Mardinly, A.R.; McCord, A.E.; Zurawski, J.; Cohen, S.; Jung, C.; Hu, L.; Mok, S.I.; Shah, A.;
Savner, E.M.; et al. Loss of inhibitory interneurons in the dorsal spinal cord and elevated itch in bhlhb5
mutant mice. Neuron 2010, 65, 886–898. [CrossRef] [PubMed]
41. Kardon, A.P.; Polgar, E.; Hachisuka, J.; Snyder, L.M.; Cameron, D.; Savage, S.; Cai, X.Y.; Karnup, S.; Fan, C.R.;
Hemenway, G.M.; et al. Dynorphin acts as a neuromodulator to inhibit itch in the dorsal horn of the spinal
cord. Neuron 2014, 82, 573–586. [CrossRef] [PubMed]
42. Bourane, S.; Duan, B.; Koch, S.C.; Dalet, A.; Britz, O.; Garcia-Campmany, L.; Kim, E.; Cheng, L.Z.; Ghosh, A.;
Ma, Q.F.; et al. Gate control of mechanical itch by a subpopulation of spinal cord interneurons. Science
2015, 350, 550–554. [CrossRef] [PubMed]
43. Andersen, H.H.; Arendt-Nielsen, L.; Gazerani, P. Glial cells are involved in itch processing. Acta Derm. Venereol.
2016, 96, 723–727. [CrossRef] [PubMed]
44. Shiratori-Hayashi, M.; Koga, K.; Tozaki-Saitoh, H.; Kohro, Y.; Toyonaga, H.; Yamaguchi, C.; Hasegawa, A.;
Nakahara, T.; Hachisuka, J.; Akira, S.; et al. Stat3-dependent reactive astrogliosis in the spinal dorsal horn
underlies chronic itch. Nat. Med. 2015, 21, 927–931. [CrossRef] [PubMed]
45. Liu, T.; Han, Q.J.; Chen, G.; Huang, Y.; Zhao, L.X.; Berta, T.; Gao, Y.J.; Ji, R.R. Toll-like receptor 4 contributes
to chronic itch, alloknesis, and spinal astrocyte activation in male mice. Pain 2016, 157, 806–817. [CrossRef]
[PubMed]
46. Zhang, Y.; Dun, S.L.; Chen, Y.H.; Luo, J.J.; Cowan, A.; Dun, N.J. Scratching activates microglia in the mouse
spinal cord. J. Neurosci. Res. 2015, 93, 466–474. [CrossRef] [PubMed]
47. Torigoe, K.; Tominaga, M.; Ko, K.C.; Takahashi, N.; Matsuda, H.; Hayashi, R.; Ogawa, H.; Takamori, K.
Intrathecal minocycline suppresses itch-related behavior and improves dermatitis in a mouse model of
atopic dermatitis. J. Investig. Dermatol. 2016, 136, 879–881. [CrossRef] [PubMed]
48. Hoeck, E.A.; Marker, J.B.; Gazerani, P.; H, H.A.; Arendt-Nielsen, L. Preclinical and human surrogate models
of itch. Exp. Dermatol. 2016, 25, 750–757. [CrossRef] [PubMed]
49. Chen, S. Clinical uses of botulinum neurotoxins: Current indications, limitations and future developments.
Toxins (Basel) 2012, 4, 913–939. [CrossRef] [PubMed]
50. Silberstein, S.D.; Aoki, K.R. Botulinum toxin type A: Myths, facts, and current research. Headache 2003, 43
(Suppl. 1), S1. [CrossRef]
51. Aoki, K.R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A.
Neurotoxicology 2005, 26, 785–793. [CrossRef] [PubMed]
52. Heckmann, M.; Heyer, G.; Brunner, B.; Plewig, G. Botulinum toxin type a injection in the treatment of lichen
simplex: An open pilot study. J. Am. Acad. Dermatol. 2002, 46, 617–619. [CrossRef] [PubMed]
53. Swartling, C.; Naver, H.; Lindberg, M.; Anveden, I. Treatment of dyshidrotic hand dermatitis with
intradermal botulinum toxin. J. Am. Acad. Dermatol. 2002, 47, 667–671. [CrossRef] [PubMed]
54. Wollina, U.; Karamfilov, T. Adjuvant botulinum toxin a in dyshidrotic hand eczema: A controlled prospective
pilot study with left-right comparison. J. Eur. Acad. Dermatol. Venereol. 2002, 16, 40–42. [CrossRef] [PubMed]
55. Breidenbach, M.A.; Brunger, A.T. New insights into clostridial neurotoxin-snare interactions. Trends Mol. Med.
2005, 11, 377–381. [CrossRef] [PubMed]
56. Dressler, D.; Saberi, F.A. Botulinum toxin: Mechanisms of action. Eur. Neurol. 2005, 53, 3–9. [CrossRef]
[PubMed]
57. Aoki, K.R. Evidence for antinociceptive activity of botulinum toxin type a in pain management. Headache
2003, 43 (Suppl. 1), S9–S15. [CrossRef] [PubMed]
Toxins 2018, 10, 143 14 of 17
58. Da Silva, L.B.; Karshenas, A.; Bach, F.W.; Rasmussen, S.; Arendt-Nielsen, L.; Gazerani, P. Blockade of glutamate
release by botulinum neurotoxin type a in humans: A dermal microdialysis study. Pain Res. Manag. 2014, 19,
126–132. [CrossRef]
59. Gazerani, P.; Au, S.; Dong, X.D.; Kumar, U.; Arendt-Nielsen, L.; Cairns, B.E. Botulinum neurotoxin type
a (bonta) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a
craniofacial muscle targeted for migraine prophylaxis. Pain 2010, 151, 606–616. [CrossRef] [PubMed]
60. Da Silva, L.B.; Poulsen, J.N.; Arendt-Nielsen, L.; Gazerani, P. Botulinum neurotoxin type a modulates
vesicular release of glutamate from satellite glial cells. J. Cell. Mol. Med. 2015, 19, 1900–1909. [CrossRef]
[PubMed]
61. Gazerani, P.; Staahl, C.; Drewes, A.M.; Arendt-Nielsen, L. Effect of botulinum toxin type a (bonta) on
capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal
sensitization. Cephalalgia 2005, 25, 990.
62. Gazerani, P.; Pedersen, N.S.; Staahl, C.; Drewes, A.M.; Arendt-Nielsen, L. Subcutaneous botulinum toxin
type a reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 2009, 141,
60–69. [CrossRef] [PubMed]
63. Da Silva, L.B.; Kulas, D.; Karshenas, A.; Cairns, B.E.; Bach, F.W.; Arendt-Nielsen, L.; Gazerani, P. Time course
analysis of the effects of botulinum neurotoxin type a on pain and vasomotor responses evoked by glutamate
injection into human temporalis muscles. Toxins 2014, 6, 592–607. [CrossRef] [PubMed]
64. Wheeler, A.; Smith, H.S. Botulinum toxins: Mechanisms of action, antinociception and clinical applications.
Toxicology 2013, 306, 124–146. [CrossRef] [PubMed]
65. Gazerani, P.; Pedersen, N.S.; Drewes, A.M.; Arendt-Nielsen, L. Botulinum toxin type a reduces
histamine-induced itch and vasomotor responses in human skin. Brit. J. Dermatol. 2009, 161, 737–745.
[CrossRef] [PubMed]
66. Leigh, A.; Nattkemper, L.A.; Stull, C.; Lavery, M.J.; Valdes-Rodriguez, R.; McGregory, M.; Ramsey, R.V.;
Chen, Y.H.; Mochizuki, H.; Yosipovitch, G. Prolonged antipruritic effect of Botulinum toxin type A on cowhage
induced itch. OP43, lecture abstracts, Abstracts from the 9th world congress on itch. Acta Derm. Venereol.
2017, 97, 1021.
67. Lieu, T.; Jayaweera, G.; Zhao, P.; Poole, D.P.; Jensen, D.; Grace, M.; McIntyre, P.; Bron, R.; Wilson, Y.M.;
Krappitz, M.; et al. The bile acid receptor tgr5 activates the trpa1 channel to induce itch in mice.
Gastroenterology 2014, 147, 1417–1428. [CrossRef] [PubMed]
68. Liu, T.; Ji, R.R. Oxidative stress induces itch via activation of transient receptor potential subtype ankyrin 1
in mice. Neurosci. Bull. 2012, 28, 145–154. [CrossRef] [PubMed]
69. Zhou, F.M.; Cheng, R.X.; Wang, S.; Huang, Y.; Gao, Y.J.; Zhou, Y.; Liu, T.T.; Wang, X.L.; Chen, L.H.; Liu, T.
Antioxidants attenuate acute and chronic itch: Peripheral and central mechanisms of oxidative stress in
pruritus. Neurosci. Bull. 2017, 33, 423–435. [CrossRef] [PubMed]
70. Cao, L.F.; Si, M.; Huang, Y.; Chen, L.H.; Peng, X.Y.; Qin, Y.Q.; Liu, T.T.; Zhou, Y.; Liu, T.; Luo, W.F. Long-term
anti-itch effect of botulinum neurotoxin a is associated with downregulation of trpv1 and trpa1 in the dorsal
root ganglia in mice. Neuroreport 2017, 28, 518–526. [CrossRef] [PubMed]
71. Rothschild, A.M. Mechanisms of histamine release by compound 48–80. Br. J. Pharmacol. 1970, 38, 253–262.
[CrossRef] [PubMed]
72. Han, S.B.; Kim, H.; Cho, S.H.; Chung, J.H.; Kim, H.S. Protective effect of botulinum toxin type a against
atopic dermatitis-like skin lesions in nc/nga mice. Dermatol. Surg. 2017. [CrossRef] [PubMed]
73. Mollanazar, N.K.; Smith, P.K.; Yosipovitch, G. Mediators of chronic pruritus in atopic dermatitis: Getting the
itch out? Clin. Rev. Allergy Immunol. 2016, 51, 263–292. [CrossRef] [PubMed]
74. Martel, B.C.; Lovato, P.; Baumer, W.; Olivry, T. Translational animal models of atopic dermatitis for preclinical
studies. Yale J. Biol Med. 2017, 90, 389–402. [PubMed]
75. Park, T.H. The effects of botulinum toxin a on mast cell activity: Preliminary results. Burns 2013, 39, 816–817.
[CrossRef] [PubMed]
76. Akhtar, N. Response to: The effects of botulinum toxin a on mast cell activity: Preliminary results. Burns
2013, 39, 817–818. [CrossRef] [PubMed]
77. Ward, N.L.; Kavlick, K.D.; Diaconu, D.; Dawes, S.M.; Michaels, K.A.; Gilbert, E. Botulinum neurotoxin a
decreases infiltrating cutaneous lymphocytes and improves acanthosis in the kc-tie2 mouse model. J. Investig.
Dermatol. 2012, 132, 1927–1930. [CrossRef] [PubMed]
Toxins 2018, 10, 143 15 of 17
78. Al-Ghamdi, A.S.; Alghanemy, N.; Joharji, H.; Al-Qahtani, D.; Alghamdi, H. Botulinum toxin: Non cosmetic
and off-label dermatological uses. J. Dermatol. Dermatol. Surg. 2015, 19, 1–8. [CrossRef]
79. Boozalis, E.; Sheu, M.; Selph, J.; Kwatra, S.G. Botulinum toxin type a for the treatment of localized recalcitrant
chronic pruritus. J. Am. Acad. Dermatol. 2018, 78, 192–194. [CrossRef] [PubMed]
80. Wood, G.J.; Akiyama, T.; Carstens, E.; Oaklander, A.L.; Yosipovitch, G. An insatiable itch. J. Pain 2009, 10,
792–797. [CrossRef] [PubMed]
81. Eisenberg, E.; Barmeir, E.; Bergman, R. Notalgia paresthetica associated with nerve root impingement. J. Am.
Acad. Dermatol. 1997, 37, 998–1000. [CrossRef]
82. Mittal, A.; Srivastava, A.; Balai, M.; Khare, A.K. A study of postherpetic pruritus. Indian Dermatol. Online J.
2016, 7, 343–344. [CrossRef] [PubMed]
83. Argoff, C.E. A focused review on the use of botulinum toxins for neuropathic pain. Clin. J. Pain 2002, 18,
S177–S181. [CrossRef]
84. Weinfeld, P.K. Successful treatment of notalgia paresthetica with botulinum toxin type A. Arch. Dermatol.
2007, 143, 980–982. [CrossRef] [PubMed]
85. Waisman, M. Solar pruritus of the elbows (brachioradial summer pruritus). Arch. Dermatol. 1968, 98, 481–485.
[CrossRef] [PubMed]
86. Kavanagh, G.M.; Tidman, M.J. Botulinum a toxin and brachioradial pruritus. Brit. J. Dermatol. 2012, 166, 1147.
[CrossRef] [PubMed]
87. Heyl, T. Brachioradial pruritus. Arch. Dermatol. 1983, 119, 115–116. [CrossRef] [PubMed]
88. Veien, N.K.; Hattel, T.; Laurberg, G.; Spaun, E. Brachioradial pruritus. J. Am. Acad. Dermatol. 2001, 44,
704–705. [CrossRef] [PubMed]
89. Walcyk, P.J.; Elpern, D.J. Brachioradial pruritus: A tropical dermopathy. Br. J. Dermatol. 1986, 115, 177–180.
[CrossRef] [PubMed]
90. Bernhard, J.D.; Bordeaux, J.S. Medical pearl: The ice-pack sign in brachioradial pruritus. J. Am. Acad. Dermatol.
2005, 52, 1073. [CrossRef] [PubMed]
91. Alai, N.N.; Skinner, H.B.; Nabili, S.T.; Jeffes, E.; Shahrokni, S.; Saemi, A.M. Notalgia paresthetica associated
with cervical spinal stenosis and cervicothoracic disk disease at c4 through c7. Cutis 2010, 85, 77–81.
[PubMed]
92. Chiriac, A.; Podoleanu, C.; Moldovan, C.; Stolnicu, S. Notalgia paresthetica, a clinical series and review. Pain Pract.
2016, 16, E90–E91. [CrossRef] [PubMed]
93. Wallengren, J.; Bartosik, J. Botulinum toxin type a for neuropathic itch. Br. J. Dermatol. 2010, 163, 424–426.
[CrossRef] [PubMed]
94. Maari, C.; Marchessault, P.; Bissonnette, R. Treatment of notalgia paresthetica with botulinum toxin A:
A double-blind randomized controlled trial. J. Am. Acad. Dermatol. 2014, 70, 1139–1141. [CrossRef]
[PubMed]
95. Morris, A.; Cardones, A.; Berger, T. Pruritic skin disease in the elderly. J. Investig. Dermatol. 2008, 128, 1606.
96. Apalla, Z.; Sotiriou, E.; Lallas, A.; Lazaridou, E.; Ioannides, D. Botulinum toxin a in postherpetic neuralgia:
A parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin. J. Pain 2013, 29, 857–864.
[CrossRef] [PubMed]
97. Salardini, A.; Richardson, D.; Jabbari, B. Relief of intractable pruritus after administration of botulinum toxin
a (botox): A case report. Clin. Neuropharmacol. 2008, 31, 303–306. [CrossRef] [PubMed]
98. Eppsteiner, E.; Boardman, L.; Stockdale, C.K. Vulvodynia. Best Pract. Res. Clin. Obstet. Gynaecol. 2014, 28,
1000–1012. [CrossRef] [PubMed]
99. Yoon, H.; Chung, W.S.; Shim, B.S. Botulinum toxin a for the management of vulvodynia. Int. J. Impot. Res.
2007, 19, 84–87. [CrossRef] [PubMed]
100. Petersen, C.D.; Giraldi, A.; Lundvall, L.; Kristensen, E. Botulinum toxin type a-a novel treatment for provoked
vestibulodynia? Results from a randomized, placebo controlled, double blinded study. J. Sex. Med. 2009, 6,
2523–2537. [CrossRef] [PubMed]
101. Berman, B.; Maderal, A.; Raphael, B. Keloids and hypertrophic scars: Pathophysiology, classification, and
treatment. Dermatol. Surg. 2017, 43, S3–S18. [CrossRef] [PubMed]
102. Perdanasari, A.T.; Torresetti, M.; Grassetti, L.; Nicoli, F.; Zhang, Y.X.; Dashti, T.; Di Benedetto, G.; Lazzeri, D.
Intralesional injection treatment of hypertrophic scars and keloids: A systematic review regarding outcomes.
Burns Trauma 2015, 3, 14. [CrossRef] [PubMed]
Toxins 2018, 10, 143 16 of 17
103. Gassner, H.G.; Sherris, D.A.; Otley, C.C. Treatment of facial wounds with botulinum toxin a improves
cosmetic outcome in primates. Plast Reconstr. Surg. 2000, 105, 1948–1953. [CrossRef] [PubMed]
104. Gauglitz, G.G.; Bureik, D.; Dombrowski, Y.; Pavicic, T.; Ruzicka, T.; Schauber, J. Botulinum toxin a for the
treatment of keloids. Skin Pharmacol. Phys. 2012, 25, 313–318. [CrossRef] [PubMed]
105. Nabai, L.; Ghahary, A. Hypertrophic scarring in the rabbit ear: A practical model for studying dermal
fibrosis. Methods Mol. Biol. 2017, 1627, 81–89. [PubMed]
106. Caliskan, E.; Gamsizkan, M.; Acikgoz, G.; Durmus, M.; Toklu, S.; Dogrul, A.; Kurt, A.; Tunca, M. Intralesional
treatments for hypertrophic scars: Comparison among corticosteroid, 5-fluorouracil and botulinum toxin in
rabbit ear hypertrophic scar model. Eur. Rev. Med. Pharmacol. 2016, 20, 1603–1608.
107. Prodromidou, A.; Frountzas, M.; Vlachos, D.E.G.; Vlachos, G.D.; Bakoyiannis, I.; Perrea, D.; Pergialiotis, V.
Botulinum toxin for the prevention and healing of wound scars: A systematic review of the literature. Plast. Surg.
2015, 23, 260–264. [CrossRef]
108. Shaarawy, E.; Hegazy, R.A.; Hay, R.M.A. Intralesional botulinum toxin type a equally effective and better
tolerated than intralesional steroid in the treatment of keloids: A randomized controlled trial. J. Cosmet.
Dermatol. US 2015, 14, 161–166. [CrossRef] [PubMed]
109. Zanchi, M.; Favot, F.; Bizzarini, M.; Piai, M.; Donini, M.; Sedona, P. Botulinum toxin type-a for the treatment
of inverse psoriasis. J. Eur. Acad. Dermatol. 2008, 22, 431–436. [CrossRef] [PubMed]
110. Brassard, D.; Benohanian, A.; Saber, M. A case of inverse psoriasis responding to botulinum toxin type A.
J. Am. Acad. Dermatol. 2011, 64, Ab161.
111. Chroni, E.; Monastirli, A.; Tsambaos, D. Botulinum toxin for inverse psoriasis? J. Eur. Acad. Dermatol. Venereol.
2009, 23, 955. [CrossRef] [PubMed]
112. Molin, S.; Diepgen, T.L.; Ruzicka, T.; Prinz, J.C. Diagnosing chronic hand eczema by an algorithm: A tool for
classification in clinical practice. Clin. Exp. Dermatol. 2011, 36, 595–601. [CrossRef] [PubMed]
113. Soler, D.C.; Bai, X.; Ortega, L.; Pethukova, T.; Nedorost, S.T.; Popkin, D.L.; Cooper, K.D.; McCormick, T.S.
The key role of aquaporin 3 and aquaporin 10 in the pathogenesis of pompholyx. Med. Hypotheses 2015, 84,
498–503. [CrossRef] [PubMed]
114. Kontochristopoulos, G.; Gregoriou, S.; Agiasofitou, E.; Nikolakis, G.; Rigopoulos, D.; Katsambas, A. Letter:
Regression of relapsing dyshidrotic eczema after treatment of concomitant hyperhidrosis with botulinum
toxin-a. Dermatol. Surg. 2007, 33, 1289–1290. [CrossRef] [PubMed]
115. Nedelec, B.; LaSalle, L. Postburn itch: A review of the literature. Wounds 2018, 30, E118–E124. [PubMed]
116. Akhtar, N.; Brooks, P. The use of botulinum toxin in the management of burns itching: Preliminary results.
Burns 2012, 38, 1119–1123. [CrossRef] [PubMed]
117. Gonzalez-Ramos, J.; Alonso-Pacheco, M.L.; Goiburu-Chenu, B.; Mayor-Ibarguren, A.; Herranz-Pinto, P.
Successful treatment of refractory pruritic fox-fordyce disease with botulinum toxin type a. Br. J. Dermatol.
2016, 174, 458–459. [CrossRef] [PubMed]
118. Ravitskiy, L.; Heymann, W.R. Botulinum toxin-induced resolution of axillary granular parakeratosis. SkinMed
2005, 4, 118–120. [CrossRef] [PubMed]
119. Ho, D.; Jagdeo, J. Successful botulinum toxin (onabotulinumtoxina) treatment of hailey-hailey disease.
J. Drugs Dermatol. 2015, 14, 68–70. [PubMed]
120. Bagherani, N.; Smoller, B.R. The efficacy of botulinum toxin type a in the treatment of hailey-hailey disease.
Dermatol. Ther. 2016, 29, 394–395. [CrossRef] [PubMed]
121. Bousquet, J.; Khaltaev, N.; Cruz, A.A.; Denburg, J.; Fokkens, W.J.; Togias, A.; Zuberbier, T.; Baena-Cagnani, C.E.;
Canonica, G.W.; van Weel, C.; et al. Allergic rhinitis and its impact on asthma (aria) 2008 update (in collaboration
with the world health organization, ga(2)len and allergen). Allergy 2008, 63 (Suppl. 86), 8–160. [CrossRef]
[PubMed]
122. International consensus report on the diagnosis and management of rhinitis. International rhinitis
management working group. Allergy 1994, 49, 1–34.
123. Zhang, E.Z.; Tan, S.; Loh, I. Botolinum toxin in rhinitis: Literature review and posterior nasal injection in
allergic rhinitis. Laryngoscope 2017, 127, 2447–2454. [CrossRef] [PubMed]
124. Ozcan, C.; Ismi, O. Botulinum toxin for rhinitis. Curr. Allergy Asthma Rep. 2016, 16, 58. [CrossRef] [PubMed]
125. Braun, T.; Gurkov, R.; Kramer, M.F.; Krause, E. Septal injection of botulinum neurotoxin a for idiopathic
rhinitis: A pilot study. Am. J. Otolaryngol. 2012, 33, 64–67. [CrossRef] [PubMed]
Toxins 2018, 10, 143 17 of 17
126. Hashemi, S.M.; Okhovat, A.; Amini, S.; Pourghasemian, M. Comparing the effects of botulinum toxin-a and
cetirizine on the treatment of allergic rhinitis. Allergol. Int. 2013, 62, 245–249. [CrossRef] [PubMed]
127. Mozafarinia, K.; Abna, M.; Khanjani, N. Effect of botulinum neurotoxin a injection into the
submucoperichondrium of the nasal septum in reducing idiopathic non-allergic rhinitis and persistent
allergic rhinitis. Iran. J. Otorhinolaryngol. 2015, 27, 253–259. [PubMed]
128. Rohrbach, S.; Junghans, K.; Kohler, S.; Laskawi, R. Minimally invasive application of botulinum toxin a in
patients with idiopathic rhinitis. Head Face Med. 2009, 5, 18. [CrossRef] [PubMed]
129. Zhu, Z.; Stone, H.F.; Thach, T.Q.; Garcia, L.; Ruegg, C.L. A novel botulinum neurotoxin topical gel: Treatment
of allergic rhinitis in rats and comparative safety profile. Am. J. Rhinol. Allergy 2012, 26, 450–454. [CrossRef]
[PubMed]
© 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
